CLBT — Cellebrite DI Ltd.
Is CLBT overbought or oversold? Here is the current MarketMoodz read.
Cellebrite DI Ltd. (CLBT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Technology name (Software - Infrastructure) last closed at $10.65. The rating moved from Neutral to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$10.65
- Last changeMoved from Neutral to Strong Oversold on November 17, 2026
- SectorTechnology
- IndustrySoftware - Infrastructure
See all oversold Technology stocks →
AI analysis
Cellebrite DI Ltd. (CLBT) benefits from steady demand for digital‑intelligence and forensics capabilities driven by govtech modernization and heightened operational resilience needs. The company’s product portfolio and recurring revenue orientation provide a path to improved visibility and cross‑sell expansion into corporate cybersecurity and investigations. Near‑term upside depends on continued ARR expansion, successful cloud/SaaS execution and margin discipline. Key headwinds include privacy and export regulations, customer concentration in public sector budgets, competition and execution risk during platform transitions. Absent strong near‑term filings or social sentiment signals, outcomes will be driven by contract wins, recurring revenue growth and clarity on regulatory exposure.
Key factors
- Exposure to govtech modernization and law‑enforcement budgets supporting recurring software and services demand
- Product suite for mobile/cloud/IoT forensics and analytics provides differentiated capabilities vs legacy toolsets
- Increasing demand for resilience, observability and patch-management post-outages should support sales of investigative and security tooling
- Recurring revenue mix and expansion opportunities (analytics, SaaS modules, cloud-based offerings) improve revenue visibility
- Opportunity to cross-sell to corporate investigations and enterprise cybersecurity customers broadens addressable market
- Relative valuation (given current price) leaves upside if execution on ARR expansion and margin improvement continues
Risks
- Regulatory/privacy/legal risk: heightened scrutiny of data‑handling, evidence admissibility and export controls could restrict sales or add compliance costs
- Customer concentration and budget risk: heavy reliance on government and law-enforcement spending could lead to revenue volatility if budget priorities shift
- Competition and technological obsolescence from specialist forensic vendors, open-source tools, or large cloud providers embedding rival capabilities
- Execution risk on SaaS/cloud transition: margins and churn could be pressured during product transitions or aggressive pricing to win contracts
- Macroeconomic and funding environment: constrained public-sector budgets or slower enterprise IT spend could depress procurement cycles
- Geopolitical/operational risks tied to international sales, export controls, and localized certification or access restrictions
- Limited social/research visibility and lack of recent filings context increase uncertainty around near-term guidance and investor sentiment
See today's live rating, score and targets
Members see the live hourly rating for CLBT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.